Recent studies indicate that overexpression of adiponectin (APN) could attenuate ischemic brain injury. However, the mechanism of APN effect remains unclear. In this study, we investigated the cellular mechanisms of APN action during cerebral ischemia. Adult mice (n ¼ 120) received an intracerebral injection of adeno-associated viral vector carrying the APN gene (AAV-APN). The mice were subjected to a transient ispilateral middle cerebral artery occlusion (tMCAO) after 7-day AAV-APN gene transfer. Cortical atrophy volume, neurological function, microvessels counts, phospho-AMPK and downstream angiogenic factor vascular endothelial growth factor (VEGF) were examined. Overexpression of APN was observed in the mouse brain following AAV-APN gene transfer. Cortical atrophy volume was attenuated in the AAV-APN-transduced mice compared with the AAV-GFP and saline-treated mice (7.9 ± 0.6%, 19.8 ± 0.3% and 20.3 ± 1.1%, respectively, Po0.05), with significant improvement in neurological function and an increased number of microvessels (199±5 vs 151±4 and 148±4 mm --2 , Po0.01). Furthermore, the expression of phospho-AMPK and VEGF were increased in the AAV-APN-transduced compared with the control mice (Po0.01), whereas inhibiting phospho-AMPK, reducing VEGF expression and attenuating the effect of APN on brain atrophy and angiogenesis (Po0.01). APN overexpression attenuates ischemia-induced brain atrophy and has improvement in neurological function. The consequence is related to promotion of focal angiogenesis. The AMPK signaling pathway has an important role in upregulating angiogenic factor VEGF.
INTRODUCTION
Ischemic stroke remains one of the most important disorders with high mortality and morbidity worldwide. Numerous neuroprotective drugs failed in clinical trials, suggesting that the role of neuroprotection alone needs to be reconsidered. 1 The success of clinical stroke therapy using t-PA indicates that restoration of blood flow is crucial for rescuing ischemic brain tissue. 2, 3 The time course of restoration is debated. However, stroke patients with a higher density of blood vessels have less morbidity and longer survival. 4, 5 These observations indicate that angiogenesis actively occurs in the ischemia region and that newly formed microvessels are important for brain repair. Our previous studies demonstrated that several angiogenic factors could attenuate ischemic brain injury, increase focal blood flow and improve neurological outcomes, suggesting that newly formed microvessels were functional. 6 --8 Ischemia upregulates endogenous vascular endothelial growth factor (VEGF) expression. However, increased endogenous VEGF is insufficient to protect brain injury, whereas exogenous VEGF can induce angiogenesis and have neuroprotective effect. 9 --11 Adiponectin (APN) is an adipocyte-specific adipocytokine. It is produced by adipocytes and secreted into the circulating system. APN is of special interest to both scientists and clinicians due to its functions in improving insulin sensitivity, its anti-atherosclerosis, and anti-inflammatory effects. 12 --14 Current studies indicate that APN has an important role in ischemic stroke. Elevated circulating APN reduces the risk of ischemic stroke, whereas low APN levels correlate with significantly increased risk of ischemic stroke. 15, 16 Low APN in ischemic stroke patients is associated with increased 5-year mortality following first-ever ischemic strokes. 17 APN is negatively correlated with brain infarct volume and the severity of cerebral infarct NIHSS score. 17 Moreover, circulating APN affects different types of ischemic stroke. The cardiogenic stroke group has the highest APN level, followed by extracranial atherosclerosis, whereas intracranial atherosclerosis has the lowest APN concentration. 18 Circulating APN is transiently decreased in acute ischemic stroke patients, and then recovers to the baseline levels 14 days later. 19 All of these studies suggest that, as a biomarker, APN is closely related to the severity of ischemic stroke.
Recent studies in a mouse model have verified that APN protects brain function from acute ischemic injury. Nishimura et al. 20 demonstrated for the first time that APN-deficient (APN-KO) mice exhibited enlarged cerebral infarctions and increased neurological deficits after ischemia-reperfusion. Supplementation of exogenous APN reduced infarct size in both APN-KO and wildtype mice. The effect of APN is mediated in part by activating endothelial nitric oxide synthase. Chen et al. 21 reported that APN exerts a neuroprotective function through its anti-inflammatory action in the early stage of ischemia. Whether other mechanisms of APN exist in its neuroprotective actions has not been clarified as yet.
APN can inhibit vascular endothelial cell apoptosis, stimulate endothelial cell differentiation and migration, and consequently promote focal angiogenesis. 22 In APN-KO mice, angiogenesis was significantly inhibited during hind limb ischemia and rescued after APN administration. 23 APN-induced angiogenesis may be mediated via the AMPK signaling pathway and upregulated VEGF expression. 24 However, the effect of APN on promoting angiogenesis in ischemic mouse brain is unknown.
In this study, we reported that APN overexpression via AAV-APN gene transfer attenuated brain atrophy and promoted focal angiogenesis in the mouse transient ispilateral middle cerebral artery occlusion (tMCAO) model. In addition, the mechanisms of APN and especially its downstream signal AMPK were explored.
RESULTS

Overexpression of APN after the AAV-APN gene transfer
Endogenous APN expression and its location in ischemic brain tissues were examined by immunohistochemistry. APN expression was clearly observed in ischemic region following 3 days of tMCAO, whereas little signal of APN was seen in the nonischemic contralateral hemisphere ( Figure 1A ). Double-immunofluorescence staining showed APN was well merged with VWF (antiVon Willebrand factor) in the ischemic region following 3 days of tMCAO, but not with NeuN (anti-neuronal nuclei) or GFAP (antiGlial fibrillary acidic protein) ( Figure 1B ). These data indicated that the expression of APN was increased in ischemic brain tissue and mainly located in endothelial cells.
To determine the effect of AAV-mediated gene transfer in the brain tissue, we examined GFP expression after AAV-GFP gene transfer. The GFP signal in the injected hemisphere would persist for at least 2 weeks ( Figure 1D ). Further study revealed that intensive APN immunoreactivity was present in the injected hemisphere of APN-transduced mice, but not in the intact contralateral hemisphere ( Figure 1C) . Importantly, APN expression in ipsilateral hemisphere significantly increased after AAV-APN gene transfer, reaching a maximum at 7 days and sustained at least 21 days (Po0.05, Figures 1E and F) .
Reduction of ischemia-induced brain atrophy in AAV-APNtransduced mice To investigate the effect of APN on ischemia-induced brain injury, cerebral atrophy volume was examined. The severity of brain atrophy was significantly smaller in the AAV-APN group than those in the GFP or saline-treated groups. Quantitative analysis revealed that atrophy volume was significantly smaller in AAV-APN-transduced mice following 14 days of tMCAO compared with the two control groups (7.9 ± 0.6% vs 19.8 ± 0.3% and 20.3 ± 1.1%, respectively, Po0.05, Figure 2 ). APN improved long-term neurobehavioral outcome To assess behavioral deficits, beam walk, rotor-rod and corner test were performed at 1, 7, 14 and 28 days, respectively, after tMCAO. Beam walk test showed that there was no difference in three groups following 1 day of tMCAO. The AAV-APN-transduced mice demonstrated significant improvements in performance at 7, 14, and 28 days after tMCAO, compared with the AAV-GFP mice and saline-treated mice group. (Po0.01, Figure 3a ) In rotor-rod test, no difference was observed after 1 day of tMCAO among groups. However, the AAV-APN-transduced mice revealed significant improvement at 7, 14, 28 days after tMCAO, compared with the other two groups. (Po0.01, Figure 3b ). Similar results were seen in corner test. (Po0.01, Figure 3c ). APN promoted angiogenesis in the ischemic brain To examine whether APN promoted focal angiogenesis in the ischemic brain, the number of microvessels was counted. The number of lectin-stained microvessels in the AAV-APN-transduced mice following 14 days of tMCAO was more than that in the AAV-GFP, the saline-treated mice and sham group (199 ± 5 mm , respectively, Po0.01, Figures 4A and B) . Similarly, the number of alpha-smooth muscle actin-stained arteries in the AAV-APN-transduced mice following 14days of tMCAO was much more than other three groups (15±1.5 mm --2 vs 4±0.5 mm --2 , 4±0.6 mm --2 and 2±0.5 mm --2 , respectively, Po0.01, Figures 4C and D) . Double fluorescence staining showed that Ki-67-positive cells were greatly increased in the AAV-APN-transduced mice. Ki-67-positive cells were located mainly at the ischemic perifocal region ( Figure 4E ). The number of the actively proliferating microvessles in the AAV-APN-transduced mice was significantly increased compared with the other two groups (Po0.01, Figure 4F ).
APN activated AMKP and upregulated VEGF expression
Compared with the AAV-GFP or saline-treated groups, VEGF expression measured at both protein and mRNA levels in the AAV-APN-transduced mice were significantly upregulated up to 14 days of tMCAO (Figures 5a and c). As AMPK activation is crucial for the function of APN, total and phosphor-AMPK levels were examined following 7 and 14 days of tMCAO. We demonstrated that Phosphor-AMPK expression in the ischemic hemisphere was significantly increased in the AAV-APN-transduced mice compared with the controls (Figure 5b ).
Inhibiting AMKP activation attenuated APN To evaluate the role of AMPK on the effect of APN, an AMPK inhibitor compound C was administered in the AAV-APNtransduced mice. Atrophy volume in the AAV-APN-transduced mice with compound C treatment was larger than in the control mice (14.7 ± 2.1% vs 7.7 ± 1.8%, Po0.05, Figure 6A ). The number of microvessels in the AAV-APN-transduced mice with compound C treatment was significantly decreased compared with the control mice (109 ± 4 mm --2 vs 200 ± 6 mm --2 , Po0.01, Figure 6B ). Meanwhile, the number of arteries in the AAV-APN-transduced mice with compound C was significantly decreased. (5±0.6 mm --2 vs 15±1.1 mm --2 , Po0.01, Figure 6C ) Similarly, Ki67-positive cells in the AAV-APN-transduced mice with compound C treatment were less than that in the controls ( Figure 6D ). Furthermore, pAMPK and VEGF in the AAV-APN-transduced mice with compound C treatment had significantly reduced protein levels. Similar results were obtained with VEGF mRNA levels. (Po0.01, Figure 6E ).
DISCUSSION
The present study demonstrates that: (1) AAV-mediated gene transfer induced APN overexpression; (2) exogenous APN attenuated ischemia-induced brain injury; and (3) APN promoted focal angiogenesis, possibly via activating the AMPK pathway and upregulating downstream angiogenetic factor VEGF. These findings suggest that APN is a novel angiogenic factor and may have an important role in promoting angiogenesis by activating the AMPK signaling pathway during cerebral ischemia.
Transduction efficiency is crucial to gene therapy. Previous studies demonstrated that when injecting AAV-vector into the lateral caudate putamen, overexpression of target genes can be achieved in both parenchyma and ependymal tissue. 25 Among the 11 AAV serotypes, serotype 2 (AAV2) is the most studied in various AAV-based research, especially in the brain. 26 In the present study, AAV2 was chosen, as serotype 2 had goodtransduction and was sustained for a long time in ischemic brain. APN overexpression reached a maximum of 7 days after gene transfer and was sustained for at least 3 weeks, suggesting that the AAV-vector is capable of transducing high level of APN in the brain.
The present study demonstrates that APN overexpression reduces ischemia-induced brain atrophy. Although we did not demonstrated the mechanism of APN during ischemia, it may be related to the inhibition of focal inflammatory response, activation of endothelial nitric oxide synthase and relaxation of blood vessels. 20 APN downregulates IL-1b, TNF-a, IL-8 and myeloperoxidase expression during cerebral ischemia; it keeps the integrity of microvascular basement membrane and reduces neutrophil infiltration. 21 In our study, VEGF expression in the ischemic region was upregulated following the overexpression of APN, which led to enhanced focal angiogenesis. As known, compensatory angiogenesis can occur in the ischemic region after cerebral ischemia, which is beneficial for increasing blood perfusion. Nevertheless, endogenous angiogenesis after a stroke is insufficient to compensate the ischemic damage. Enhancement of angiogenesis is a promising strategy explored by many research groups. Angiogenesis is a step-by-step process, involving an increase of vascular permeability, degradation of surrounding matrix, proliferation and migration of endothelial cells, and stabilization of newly formed microvessels. 27 Concerted actions of many angiogenic molecules are needed in this process, in which VEGF is the most essential in each step of angiogenesis. 28, 29 Our results suggest that APN exerts a cerebroprotective function through angiogenesis by upregulating VEGF. Furthermore, the reduction of brain atrophy may be related to the inhibition of focal inflammatory response, activation of endothelial nitric oxide synthase, relaxation of blood vessels, 20 and downregulation in IL-1b, TNF-a, IL-8 and myeloperoxidase expression during cerebral ischemia. 21 Ischemic/hypoxic stress activates AMPK signaling pathway in cell cultures, which is related to the increase of the AMP/ATP ratio. Hypoxia induces the AMPK phosphorylation in human umbilical vein endothelial cells and promotes cell migration and differentiation, whereas the inhibition of AMPK phosphorylation blocks human umbilical vein endothelial cells migration and differentiation. 30 In the mouse ischemic hind limb model, the AMPK antagonist AICAR upregulates VEGF expression, whereas dominant-negative AMPK abolishes the AICAR-induced VEGF expression. 31 These results suggest that the expression of VEGF might be regulated in ischemic tissue through the AMPK signaling pathway.
APN promotes focal angiogenesis mediated by the AMPK pathway in both the mouse ischemic hind limb and the transverse aortic constriction models. However, whether APN stimulates angiogenesis in cerebral tissue through the same pathway remains unknown. APN enhanced AMPK phosphorylation after an ischemic stroke. Inhibiting AMPK phosphorylation by compound C significantly attenuated VEGF expression and angiogenesis in the ischemic penumbra, indicating that the effect of APN on angiogenesis is related to AMPK activation during cerebral ischemia.
In conclusion, the above experiments have demonstrated that overexpression of APN upregulated VEGF expression and angiogenesis occurred after brain ischemia. The effect is mediated by the AMPK signaling pathway. The present results suggest that APN can have a positive role during brain ischemia and might have therapeutic potential for the treatment of ischemic stroke. 
MATERIALS AND METHODS
Experimental groups
The Institutional Animal Use and Care Committee at School of Medicine, Shanghai Jiao Tong University approved the experimental procedures for the use of laboratory animals. The first experiment was designed to examine transduction efficiency. Two groups of adult male CD-1 mice weighing 30 --35 g received AAV-APN or AAV-GFP transduction (n ¼ 15 per group). The second experiment was to explore the effect of AAV-APN on promoting angiogenesis in the mouse tMCAO model. Three groups of CD-1 mice underwent AAV-APN, AAV-GFP or saline injection (n ¼ 30 per group). Seven days after AAV-vector intracerebral injection, the mice underwent tMCAO followed by 14 days of reperfusion. The number of microvessels and the expression of angiogenic factors were then examined to determine the effect of APN on angiogenesis in this ischemic mouse brain model.
AAV-APN gene transfer in the mouse brain
Adult male mice were anesthetized intraperitoneally using ketamine/ Xylazine (100/10 mg kg --1 body weight), and then placed in a stereotactic frame (David Kopf Instruments, Tujunga, CA, USA). A burr hole was drilled in the pericranium 2 mm lateral to the sagittal suture and 1 mm posterior to the coronal suture. A 10 ml Hamilton syringe was stereotactically inserted into 2.5 mm deeper to the cortex. Viral suspension of 5 ml containing 4 Â 10 9 genome copies of AAV-APN was injected via a micro-pump (WPI Inc., Sarasota, FL, USA) at a rate of 0.2 ml min --1 based on our previous study. 32 The needle was withdrawn after 15 min of injection. The animals then were allowed to recover and returned to their home cages.
Middle cerebral artery occlusion in mice
Transient MCAO was performed on day 7 after AAV-APN gene transfer. The surgical procedure has been described previously. 33 Briefly, the left common carotid artery was visualized and isolated under an operating microscope (Leica, Wetzlar, Germany). A silicone-coated 6-0 dermalon suture was gently inserted from the ECA stump to the ICA, and stopped at the opening of the MCA. The distance from the bifurcation of ICA/ECA to MCA was 10 ± 0.5 mm. Successful occlusion and reperfusion was verified by laser Doppler flowmetry (Moor Instruments, Devon, England). Reperfusion was performed by suture withdrawal after 1 h of MCAO.
Administration of compound C
In one group of AAV-APN-transduced mice, compound C (Sigma, St Louis, MO, USA, 20 mg kg --1 ), 34 a selective pharmacological AMPK inhibitor, was injected intraperitoneally 1 day before tMCAO, then three times per week until the animals were killed, according to the cited paper. Since the compound C exerts its effects within minutes and half-life of compound C is 2.6 days, 34 we then repeated compound C administration to maintain the effective compound C level in the mouse.
Behavioral tests
Behavioral tests were carried out before tMCAO, and 1, 7, 14 and 28 days after tMCAO. The mice were trained for 3 days before tMCAO with three consecutive trials to get baseline values. (1) Beam walk test: mice were trained to traverse a wooden beam (diameter 7 mm), elevated 60 cm above the floor, to go back to their home cage. Mice were placed on one end of the beam and the latency time to traverse the central 80% of the beam towards the enclosed escape platform was recorded. If the animal failed to cross the beam within 60s, the latency time was recorded as 60s for statistical analysis. 35 (2) Rotor-Rod test: mice were required to balance on a rotating rod. The animals were placed on a rod that accelerated gradually from 0 --40 r.p.m. over 4 min, then the length of time remaining on the rod (fall latency) was recorded. 35 (3) Corner test: a mouse was placed between two boards (30 Â 20 Â 1 cm 3 ), which were attached at a 301 angle with a small opening as described in zhang et al. 36 The mouse reared forward and upward, then turned back to face the open end. The turns in one versus the other direction were recorded from 10 trails for each test. Right turn percentage was calculated.
Western blot analysis
Tissue samples were collected and 30 mg of protein was separated by 10% SDS --PAGE electrophoresis and transferred to a nitrocellulose membrane (Whatman, Dassel, Germany). The membranes were treated with anti-AMPK and anti-pAMPK (1:1000 dilution, Cell Signaling, Beverly, MA, USA), anti-VEGF (1:500 dilution, Santa Cruz Biotechnology, Santa Cruz, CA, USA), anti-APN (1:500 dilution, R&D, Minneapolis, MN, USA). They were then visualized using an ECL system (Thermo, Rockford, IL, USA). Membrane images were taken and measurements made as Gel Doc XR Systems (BioRad, Hercules, CA, USA).
Brain atrophy measurement
Brains were removed and frozen immediately in À40 1C isopentane solution. Twenty-mm thick sections were cut from the frontal pole and stained using cresyl violet. Brain atrophy volume was analyzed via Image J software (NIH). The atrophy volume was calculated by the following formula: contralateral hemisphere brain area minus infarct hemisphere area, then multiplied by the section interval thickness. Grove, PA, USA) was applied and double-labeled immunostaining was evaluated using a fluorescence microscope (Leica, DM 2500).
The VECTASTAIN Elite ABC system was used for DAB staining. Sections were incubated with anti-APN antibody as above, and then with biotinylated secondary antibody (1:5000 dilution, Vector Labs). The sections were observed with a light microscope.
Quantitative real-time PCR RNA from each brain sample was isolated using Trizol reagent (Invitrogen, Carlsbad, CA, USA) and reverse-transcribed into complementary DNA using the Reverse Transcription System (Takara, Shanghai, China). Quantitative RT-PCR analysis was performed on the PRISM 7900HT (ABI, Foster City, CA, USA) using SYBR PrimeScripttm RT-PCR Kit II Systems (Takara). Raw thredhold-cycle (Ct) values were obtained from SDS 2.0 software (Applied Biosystems, Rotkreuz, Switzerland). The primers used were: 5 0 -CTGTAAC GATGAAGCCCTGGAG-3 0 (forward) and 5 0 -TGGTGAGGTTTGATCCGCAT-3 0 (reverse) for mouse VEGF-A; 5 0 -AGGTCGGTGTGAACGGATTTG-3 0 (forward) and 5
0 -TGTAGACCATGTAGTTGAGGTCA-3 0 (reverse) for mouse GAPDH. Relative quantities (RQ) was calculated according to the formula RQ ¼ E-Ct using an efficiency (E) of 2 by default. Gene expression of VEGF was normalized to that of GAPDH measured in the same sample, and then expressed as an increase over control.
Microvessel counts
Two brain sections 1 mm anterior and 1 mm posterior to the needle track of the each brain and the left, right, and bottom area of the needle track were chosen for each section. The number of microvessels was counted via lectin staining and carried out using a 10 Â objective lens. The microvessels with a defined lumen or a well-defined linear vessel shape were counted. The number of microvessels was obtained from the averaged number of microvessels of six pictures. 37 The number of arteries was calculated in the same way. 38 
Statistical analysis
Data were presented as mean ± s.d. Comparison of the two groups was analyzed by an unpaired student t-test. Three group comparison data were analyzed by one-tailed ANOVA and one-tailed ANOVA with Dunnett's multiple comparison. A probability value of o5% was accepted as statistically significant.
